Sanofi's Beyfortus injection succeeds in US RSV study
- Sanofi (NASDAQ:SNY) said that a recent U.S. study found that its Beyfortus (nirsevimab) injection successfully met its main goals, showing that it helps protect infants from respiratory syncytial virus (RSV) illness.
- The research revealed an 87% decrease in RSV cases among healthy, full-term babies born before or during the RSV season, across various healthcare settings.
- Additionally, the study indicated a 98% reduction in hospitalizations for babies with RSV who received Beyfortus, co-developed with AstraZeneca (NASDAQ:AZN), compared to those who did not.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.